ArticleJournal of pain research2026
Impact of UGT1A9 Expression on Analgesic Efficacy and Safety of Postoperative Ketorolac in Thyroid Cancer Surgery: A Prospective Cohort Study.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Ketorolac tromethamine is a key opioid-sparing analgesic in Enhanced Recovery After Surgery (ERAS) protocols for thyroid cancer surgery; however, clinically significant interindividual variability in its analgesic efficacy and adverse-event profile is frequently observed. Because UDP-glucuronosyltransferase 1A9 (UGT1A9) plays a central role in the metabolic clearance of ketorolac, we hypothesized that preoperative UGT1A9 expression levels would be associated with differences in postoperative analgesic outcomes. Methods: This prospective observational cohort study enrolled 150 ASA I-II patients undergoing elective total thyroidectomy with central lymph node dissection. Preoperative peripheral blood UGT1A9 protein expression was quantified by enzyme-linked immunosorbent assay (ELISA; optical density, OD). Patients were stratified by median OD into a high-expression cohort (Group I, n = 75) and a low-expression cohort (Group II, n = 75). All received 30 mg intravenous ketorolac at wound closure; no patient-controlled analgesia was used. Primary outcome: resting VAS pain scores at 4 h (T1), 6 h (T2), 8 h (T3), and 12 h (T4). Secondary outcomes: serum IL-6 and CRP at 12 h, adverse events, and length of hospital stay (LOS). Results: Baseline characteristics were comparable (all p > 0.05). From T2 onward, Group II (low expression) demonstrated lower VAS scores than Group I (e.g. T3: 1.47 ± 0.55 vs. 2.00 ± 0.90; p < 0.001; Cohen's d = 0.70). At 12 h, IL-6 and CRP were significantly lower in Group II (both p < 0.001). LOS was shorter in Group II (7.19 ± 1.44 vs. 8.69 ± 1.85 days; p < 0.001). The incidence of mild dizziness was higher in Group II (9.3% vs. 1.3%; p = 0.029, Fisher's exact test). Conclusion: These preliminary findings suggest that preoperative UGT1A9 expression may be associated with postoperative ketorolac analgesic response in thyroid cancer surgery. This study provides hypothesis-generating evidence for future pharmacokinetic/pharmacodynamic validation studies exploring pharmacogenomic individualization of perioperative NSAID analgesia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.